跳至主要内容
临床试验/NCT03302026
NCT03302026已完成不适用

A Proof-of-concept Study of Real-time fMRI Neurofeedback Training for Smoking Cessation

University of Pennsylvania1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2018年1月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
46
试验地点
1
主要终点
Smoking Lapse Paradigm

研究概览

简要总结

This study will examine how real-time functional magnetic resonance imaging (rt-fMRI) feedback can be used to modulate brain activation in the context of smoking cues in order to resist craving. Participants will complete a total of three fMRI scanning sessions with a cue suppression task with or without neurofeedback training (NFT). Participants will be randomized to an active group (active NFT) or a control group (no NFT) during the scanning sessions. At the end of the third session, all participants will complete a validated smoking lapse laboratory paradigm to evaluate effects of NFT on smoking behavior.

详细描述

Smoking is the greatest preventable cause of mortality and a significant economic burden. Even with the best available treatments, most smokers relapse within days or weeks after a quit attempt. Nicotine replacement therapy, the most widely used pharmacotherapy, yields end of treatment quit rates of <25% suggesting that managing nicotine withdrawal is not sufficient. A smoker's response to smoking cues is one factor that increases risk of relapse. This study will examine how real-time functional magnetic resonance imaging (rt-fMRI) feedback can be used to modulate brain activation in the context of smoking cues in order to resist craving. First, we will conduct a pilot study in 12 smokers for technical development and to evaluate the feasibility of the proposed study procedures. Participants will complete a total of three fMRI scanning sessions with a cue suppression task with or without neurofeedback training (NFT). Participants will be randomized to an active group (active NFT) or a control group (no NFT) during the scanning sessions. At the end of the third session, all participants will complete a validated smoking lapse laboratory paradigm to evaluate effects of NFT on smoking behavior. Upon successful completion of the technical development phase, we will proceed to a proof-of-concept phase, which will recruit 72 smokers to evaluate the efficacy of NFT for smoking behavior.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

Treatment-seeking smokers complete an intake session and then be randomized to an active NFT group or a control group.

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Treatment-seeking smokers between the ages of 18 and 65, reporting consumption of at least 10 cigarettes per day for at least the past 6 months;
  • •Planning to live in the area for at least the next month;
  • •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form;
  • •Able to communicate fluently in English (speaking, writing, and reading).

排除标准

  • •Smoking Behavior:
  • •Use of chewing tobacco or snuff or cigars;
  • •Current enrollment or plans to enroll in another smoking cessation program or research study in the next month;
  • •Current or anticipated (within the next month) use of smoking cessation medications or nicotine replacement therapy (NRT);
  • •A baseline carbon monoxide (CO) reading less than 10ppm.
  • •Alcohol/Drugs:
  • •Current alcohol consumption that exceeds 25 standard drinks/week;
  • •Positive breath alcohol concentration test (BrAC greater than or equal to 0.01) at intake; a. Participants testing positive for breath alcohol with a reading equal to or greater than .08 (the legal driving limit) or who are visibly impaired will be instructed not to drive themselves home after the appointment. If a participant needs to use a phone to call for a safe ride home, an office telephone will be made available to the participant.
  • •Medication:
  • •Current use or recent discontinuation (within the past 30 days at the time of Intake) of:
  • •Smoking cessation medication (e.g., Zyban, Wellbutrin, Wellbutrin SR, Chantix, NRT);
  • •Anti-psychotic medications;
  • •Any medication that could compromise participant safety as determined by the Principal Investigator and/or Study Physician;
  • •Daily use of:
  • •Opiate-containing medications for chronic pain.
  • •Medical/Neuropsychiatric:
  • •Women who are pregnant, planning a pregnancy, and/or breast feeding. All female subjects of childbearing potential will undergo a urine pregnancy test at Intake and at each scan session.
  • •History of epilepsy or a seizure disorder;
  • •History of stroke;
  • •Self-reported brain (or CNS) or spinal tumor;
  • •Self-reported history of head trauma;
  • •Self-reported history or current diagnosis of psychosis.
  • •fMRI-Related:
  • •Self-reported use of pacemakers, certain metallic implants, or presence of metal in the eye as contraindicated for fMRI;
  • •Self-reported history of claustrophobia;
  • •Being left-handed;
  • •Color blindness;
  • •Weight greater than 250lbs at intake;
  • •Self-reported history of gunshot wounds;
  • •Any impairment preventing participants from using the response pad necessary for the computer tasks;
  • •Circumstances or conditions that may interfere with magnetic resonance imaging (MRI).
  • •General Exclusion:
  • •Any medical condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator;
  • •Enrollment or plans to enroll in another research study;
  • •Inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator.

研究组 & 干预措施

Real-time neurofeedback training group

Experimental

We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In this arm, participants will complete four sessions: an intake session and 3 neurofeedback scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.

干预措施: Realtime biofeedback using fMRI (Behavioral)

No-feedback control group

No Intervention

We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In the control group arm, participants will complete four sessions: an intake session and 3 scanning visits with no neurofeeback. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.

结局指标

主要结局

Smoking Lapse Paradigm

时间窗: Study session 3 (scan day 3)

Time (sec) to first cigarette during a 50 minute monitored smoking lapse period in smoking laboratory

次要结局

  • Cue induced brain signal change(Study session 3 (scan day 3))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Real Time fMRI and Quitting Smoking | 临床试验